Pulmonx (STU:4NI) Institutional Ownership : 59.66% (As of Jun. 20, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pulmonx's institutional ownership is 59.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pulmonx's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pulmonx's Float Percentage Of Total Shares Outstanding is 70.12%.

Pulmonx Institutional Ownership Historical Data

The historical data trend for Pulmonx's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Institutional Ownership Chart

Pulmonx Historical Data

The historical data trend for Pulmonx can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	51.85	51.36	52.32	49.79	52.55	53.20	55.15	57.36	59.67	59.66

Pulmonx Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Pulmonx (STU:4NI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (STU:4NI) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

LUNG:USA

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Pulmonx (STU:4NI) Headlines

No Headlines